Revlimid, Velcade and dexamethasone (RVd) are one of the preferred induction therapies prior to transplant. With the good outcomes seen by adding daratumumab to these standard therapies for relapsed or refractory patients, researchers want to know if adding dara to RVD will help extend outcomes if added at the beginning of treatment. Peter Voorhees, MD from the Levine Cancer Institute shares a clinical trial for newly diagnosed patients who are eligible for a stem cell transplant. Patients are either given either Dara-RVD or RVD prior to stem cell transplant. Patients will be tested for depth of response after the therapy. The study is open at 43 centers across the United States. To learn more, click the button below and watch Dr. Voorhees present earlier study results using Dara-RVD on Myeloma Crowd TV. Dara with RVD for Newly Diagnosed Patients
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).